『徳島大学 教育・研究者情報データベース (EDB)』---[学外] /
ID: Pass:

登録内容 (EID=336618)

EID=336618EID:336618, Map:0, LastModified:2025年8月13日(水) 13:12:13, Operator:[[ADMIN]], Avail:TRUE, Censor:承認済, Owner:[片桐 豊雅], Read:継承, Write:継承, Delete:継承.
種別 (必須): 学術論文 (審査論文) [継承]
言語 (必須): 英語 [継承]
招待 (推奨):
審査 (推奨):
カテゴリ (推奨):
共著種別 (推奨):
学究種別 (推奨):
組織 (推奨):
著者 (必須): 1. (英) Obara Wataru (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
2. (英) Kanehira Mitsugu (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
3.片桐 豊雅
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
4. (英) Kato Renpei (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
5. (英) Kato Yoichiro (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
6. (英) Takata Ryo (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
題名 (必須): (英) Present status and future perspective of peptide-based vaccine therapy for urological cancer.  (日)    [継承]
副題 (任意):
要約 (任意): (英) Use of peptide-based vaccines as therapeutics aims to elicit immune responses through antigenic epitopes derived from tumor antigens. Peptide-based vaccines are easily synthesized and lack significant side-effects when given in vivo. Peptide-based vaccine therapy against several cancers including urological cancers has made progress for several decades, but there is no worldwide approved peptide vaccine. Peptide vaccines were also shown to induce a high frequency of immune response in patients accompanied by clinical efficacy. These data are discussed in light of the recent progression of immunotherapy caused by the addition of immune checkpoint inhibitors thus providing a general picture of the potential therapeutic efficacy of peptide-based vaccines and their combination with other biological agents. In this review, we discuss the mechanism of the antitumor effect of peptide-based vaccine therapy, development of our peptide vaccine, recent clinical trials using peptide vaccines for urological cancers, and perspectives of peptide-based vaccine therapy.  (日)    [継承]
キーワード (推奨):
発行所 (推奨):
誌名 (必須): Cancer Science ([日本癌学会])
(pISSN: 1347-9032, eISSN: 1349-7006)

ISSN (任意): 1349-7006
ISSN: 1347-9032 (pISSN: 1347-9032, eISSN: 1349-7006)
Title: Cancer science
Title(ISO): Cancer Sci
Publisher: Wiley-Blackwell
 (NLM Catalog  (医中誌Web  (Scopus  (CrossRef (Scopus information is found. [need login])
[継承]
[継承]
(必須): 109 [継承]
(必須): 3 [継承]
(必須): 550 559 [継承]
都市 (任意):
年月日 (必須): 西暦 2018年 2月 15日 (平成 30年 2月 15日) [継承]
URL (任意):
DOI (任意): 10.1111/cas.13506    (→Scopusで検索) [継承]
PMID (任意): 29345737    (→Scopusで検索) [継承]
CRID (任意):
Scopus (任意):
機関リポジトリ : 112379 [継承]
researchmap (任意):
評価値 (任意):
被引用数 (任意):
指導教員 (推奨):
備考 (任意): 1.(英) PublicationType: Journal Article  (日)    [継承]
2.(英) PublicationType: Review  (日)    [継承]

標準的な表示

和文冊子 ● Wataru Obara, Mitsugu Kanehira, Toyomasa Katagiri, Renpei Kato, Yoichiro Kato and Ryo Takata : Present status and future perspective of peptide-based vaccine therapy for urological cancer., Cancer Science, 109, 3, 550-559, 2018.
欧文冊子 ● Wataru Obara, Mitsugu Kanehira, Toyomasa Katagiri, Renpei Kato, Yoichiro Kato and Ryo Takata : Present status and future perspective of peptide-based vaccine therapy for urological cancer., Cancer Science, 109, 3, 550-559, 2018.

関連情報

Number of session users = 2, LA = 1.21, Max(EID) = 467622, Max(EOID) = 1242991.